NCAN

NCAN encodes neurocan, a chondroitin sulfate proteoglycan predominantly expressed in the brain but also detected in liver, that modulates cell adhesion and migration through its extracellular matrix interactions (PMID:9795216, PMID:24946282). The hyaluronan-binding domain of neurocan is sufficient to engage hyaluronan in the brain extracellular matrix, including perineuronal nets and interstitial matrix, as demonstrated by colocalization with hyaluronan-binding protein and sensitivity to hyaluronidase digestion. NCAN is upregulated in periventricular white matter and cortex following inflammatory CNS injury, coinciding with neuronal progenitor cell proliferation and migration, implicating it in lesion-associated extracellular matrix remodeling (PMID:21107918).

1. 1998 Medium

   Cloning of the human NCAN gene established that neurocan is a brain-specific chondroitin sulfate proteoglycan of 1321 amino acids involved in modulation of cell adhesion and migration, resolving its molecular identity and genomic organization.

   Evidence cDNA cloning, Northern analysis, chromosomal mapping, and genomic sequencing of the human gene

   PMID:9795216

   Open questions at the time

   • No functional perturbation experiment to directly test adhesion/migration roles
   • Brain-specific expression claim based on Northern blot alone; expression in other tissues not systematically surveyed
   • No identification of specific binding partners or receptors
2. 2010 Medium

   Demonstration that NCAN is upregulated in white matter and cortex during inflammatory demyelination linked neurocan to injury-associated extracellular matrix remodeling coincident with neural progenitor cell activity.

   Evidence EAE mouse model with immunofluorescence, GFAP staining, and BrdU labeling of neural progenitor cells

   PMID:21107918

   Open questions at the time

   • Correlative — no loss-of-function or gain-of-function manipulation of NCAN in the injury model
   • Causal relationship between NCAN upregulation and progenitor migration not tested
   • Mechanism by which NCAN influences progenitor behavior unknown
3. 2014 Medium

   Detection of NCAN protein in human liver tissue by RT-PCR and immunofluorescence expanded the expression map beyond the nervous system and connected the rs2228603 polymorphism to hepatocellular carcinoma risk in alcoholic liver disease.

   Evidence RT-PCR, immunofluorescence microscopy, and genotyping in patient cohorts

   PMID:24946282

   Open questions at the time

   • Functional role of neurocan in liver tissue is unknown
   • Mechanism linking rs2228603 to hepatocellular carcinoma not characterized
   • Single cohort association; no mechanistic follow-up
4. 2025 Medium

   Isolation of the hyaluronan-binding domain showed it is sufficient for engagement with brain extracellular matrix including perineuronal nets, establishing the minimal structural element responsible for NCAN–hyaluronan interaction.

   Evidence AAV-mediated secretion of NCAN HA-binding domain–GFP fusion, colocalization with HABP, hyaluronidase sensitivity assay in mouse brain (preprint)

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Contribution of the chondroitin sulfate chains versus the HA-binding domain to in vivo function not dissected
   • Downstream signaling consequences of HA binding not addressed

• The precise cellular mechanisms by which neurocan modulates cell adhesion, migration, and neural progenitor behavior remain unresolved, as no loss-of-function studies in mammalian systems have dissected its non-redundant roles in brain or liver.
• No genetic knockout or conditional deletion phenotype reported in the timeline
• Specific cell-surface receptors or signaling pathways engaged by neurocan are unidentified
• Functional significance of hepatic neurocan is entirely uncharacterized